Results 171 to 180 of about 20,268 (224)

Understanding the patient experience of heart failure with obesity and preserved ejection fraction (HFpEF): qualitative insights from patients and clinicians. [PDF]

J Patient Rep Outcomes
Kanu C, Al-Zubeidi T, Shinde S, Al-Jassar G, Poon JL, Miller J, Marshall C, Carmichael C.   +7 more
europepmc   +1 more source

Diagnosis and treatment of HFpEF

Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics
openaire   +2 more sources

Clinical utility of the four-dimensional automatic left atrial quantification technique in evaluating left atrial volume and function in patients with heart failure with preserved ejection fraction. [PDF]

Quant Imaging Med Surg
Cheng Y, Zhang L, Li L, Fei M, Wang Y, Zhang P.   +5 more
europepmc   +1 more source

Mitochondrial Targeting by Elamipretide Improves Myocardial Bioenergetics Without Translating into Functional Benefits in HFpEF. [PDF]

Int J Mol Sci
Schauer A, Jahn D, Vahle B, Barthel P, Männel A, Fabig G, Linke A, Adams V, Augstein A.   +8 more
europepmc   +1 more source

Heart failure evidence update 2026. [PDF]

Heart Fail Rev
Liori S, Kapelios CJ, Savarese G, Filippatos G.   +3 more
europepmc   +1 more source

Temporal changes in first-phase ejection fraction during evolution of heart failure with preserved ejection fraction and afterload-induced heart failure in mice. [PDF]

J Physiol Biochem
Gu H, Catibog N, Zhao Y, Visnagri A, Chowienczyk PJ, Shah AM, Zhang M.   +6 more
europepmc   +1 more source

Effect of sodium-glucose cotransporter-2 inhibitors on uric acid in patients with heart failure and preserved ejection fraction: a retrospective analysis in real word. [PDF]

BMC Cardiovasc Disord
Lv F, Zhang D, Xu C, Xu X.
europepmc   +1 more source

Galectin-1 Is a Marker but Not a Mediator of Heart Failure With Preserved Ejection Fraction. [PDF]

Hypertension
Wassenaar JW, Smart CD, Fehrenbach DJ, Shuey MM, Sangowdar P, Zhong L, Miller FJ, Wells QS, Huang S, Collins SP, Storrow AB, Miller KF, Gupta DK, Doran AC, Madhur MS.   +14 more
europepmc   +1 more source

Differential cardiovascular benefits of SGLT2 inhibitors, sacubitril/valsartan, omecamtiv mecarbil, and vericiguat across heart failure phenotypes: a systematic review and meta-analysis. [PDF]

Front Pharmacol
Wang M, Zuo Z, Wu T, Zhou Z.
europepmc   +1 more source